These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Anderson-Fabry disease: a protean clinical behavior and a chance diagnosis. Amico L; Visconti G; Amato A; Azzolina V; Sessa A; Li Vecchi M J Nephrol; 2005; 18(6):770-2. PubMed ID: 16358237 [TBL] [Abstract][Full Text] [Related]
26. Agalsidase: a second look. With hindsight: full data challenge efficacy. Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828 [No Abstract] [Full Text] [Related]
27. Fabrazyme--recombinant protein treatment for Fabry's disease. Barngrover D J Biotechnol; 2002 May; 95(3):280-2. PubMed ID: 12080957 [No Abstract] [Full Text] [Related]
28. Spotlight on agalsidase beta in Fabry disease. Keating GM; Simpson D BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124 [TBL] [Abstract][Full Text] [Related]
29. Enzyme therapy for Fabry's disease: registered for success? Knebelmann B; Kurschat C; Thadhani R Lancet; 2009 Dec; 374(9706):1950-1. PubMed ID: 19959220 [No Abstract] [Full Text] [Related]
36. Fabry disease--whom to treat and when. Mehta A Clin Ther; 2008; 30 Suppl B():S43-4. PubMed ID: 18395136 [No Abstract] [Full Text] [Related]
37. Fabry disease: focus on cardiac manifestations and molecular mechanisms. Perrot A; Osterziel KJ; Beck M; Dietz R; Kampmann C Herz; 2002 Nov; 27(7):699-702. PubMed ID: 12439642 [TBL] [Abstract][Full Text] [Related]
38. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study. Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478 [TBL] [Abstract][Full Text] [Related]
39. PR interval and the response to enzyme-replacement therapy for Fabry's disease. Waldek S N Engl J Med; 2003 Mar; 348(12):1186-7. PubMed ID: 12646684 [No Abstract] [Full Text] [Related]